Dobrivoje Stokic

Dobrivoje Stokic

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2003 in JAMA
Verified
Journal Article
Open access
PDF file
JSJames Sejvar
James Sejvar
MHMaryam B. Haddad
Maryam B. Haddad
BTBruce C. Tierney
Bruce C. Tierney
GCGrant L. Campbell
Grant L. Campbell
AMAnthony A. Marfin
Anthony A. Marfin
LPLyle R. Petersen
Lyle R. Petersen
Most human infections with West Nile virus (WNV) are subclinical or manifest as a mild febrile illness, but a small proportion of patients (<1%) develop acute neurologic illness.1-4 Although recent WNV outbreaks have been associated with severe neurologic disease,1-5 retrospective studies have failed to identify clinical features that distinguish WNV from other viral encephalitides.1,5-9 The US outbreak of WNV in 200210 presented an opportunity to assess neurologic manifestations, laboratory and neurodiagnostic findings, and outcome associated with WNV infection.1,7,11

1 December 1994 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MRM B Reid
M B Reid
DSDobrivoje Stokic
Dobrivoje Stokic
SKS M Koch
S M Koch
FKF A Khawli
F A Khawli
ALA A Leis
A A Leis
N-acetylcysteine (NAC) is a nonspecific antioxidant that selectively inhibits acute fatigue of rodent skeletal muscle stimulated at low (but not high) tetanic frequencies and that decreases contractile function of unfatigued muscle in a dose-dependent manner. The present experiments test the hypothesis that NAC pretreatment can inhibit acute muscular fatigue in humans. Healthy volunteers were studied on two occasions each. Subjects were pretreated with NAC 150 mg/kg or 5% dextrose in water by intravenous infusion. The subject then sat in a chair with surface electrodes positioned over the motor point of tibialis anterior, an ankle dorsiflexor of mixed-fiber composition. The muscle was stimulated to contract electrically (40-55 mA, 0.2-ms pulses) and force production was measured. Function of the unfatigued muscle was assessed by measuring the forces produced during maximal voluntary contractions (MVC) of ankle dorsiflexor muscle groups and during electrical stimulation of tibialis anterior at 1, 10, 20, 40, 80, and 120 Hz (protocol 1). Fatigue was produced using repetitive tetanic stimulations at 10 Hz (protocol 1) or 40 Hz (protocol 2); intermittent stimulations subsequently were used to monitor recovery from fatigue. The contralateral leg then was studied using the same protocol. Pretreatment with NAC did not alter the function of unfatigued muscle; MVC performance and the force-frequency relationship of tibialis anterior were unchanged. During fatiguing contractions stimulated at 10 Hz, NAC increased force output by approximately 15% (P < 0.0001), an effect that was evident after 3 min of repetitive contraction (P < 0.0125) and persisted throughout the 30-min protocol. NAC had no effect on fatigue induced using 40 Hz stimuli or on recovery from fatigue. N-acetylcysteine pretreatment can improve performance of human limb muscle during fatiguing exercise, suggesting that oxidative stress plays a causal role in the fatigue process and identifying antioxidant therapy as a novel intervention that may be useful clinically.

1 July 2003 in Emerging Infectious Diseases
Verified
Journal Article
Open access
JSJames Sejvar
James Sejvar
ALA. Arturo Leis
A. Arturo Leis
DSDobrivoje Stokic
Dobrivoje Stokic
JGJay A. Van Gerpen
Jay A. Van Gerpen
AMAnthony A. Marfin
Anthony A. Marfin
LPLyle R. Petersen
Lyle R. Petersen
Acute weakness associated with West Nile virus (WNV) infection has previously been attributed to a peripheral demyelinating process (Guillain-Barré syndrome); however, the exact etiology of this acute flaccid paralysis has not been systematically assessed. To thoroughly describe the clinical, laboratory, and electrodiagnostic features of this paralysis syndrome, we evaluated acute flaccid paralysis that developed in seven patients in the setting of acute WNV infection, consecutively identified in four hospitals in St. Tammany Parish and New Orleans, Louisiana, and Jackson, Mississippi. All patients had acute onset of asymmetric weakness and areflexia but no sensory abnormalities. Clinical and electrodiagnostic data suggested the involvement of spinal anterior horn cells, resulting in a poliomyelitis-like syndrome. In areas in which transmission is occurring, WNV infection should be considered in patients with acute flaccid paralysis. Recognition that such weakness may be of spinal origin may prevent inappropriate treatment and diagnostic testing.

17 October 2002 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ALA. Arturo Leis
A. Arturo Leis
DSDobrivoje Stokic
Dobrivoje Stokic
JPJo Lynn Polk
Jo Lynn Polk
VDVictor Dostrow
Victor Dostrow
MWMichael Winkelmann
Michael Winkelmann
Muscle weakness is a common finding and an important predictor of death in patients with West Nile virus encephalitis.1,2 Yet this important sign does not have a defined pathological basis. In monkeys, horses, and birds, West Nile virus causes poliomyelitis.3-5 Our clinical and electrodiagnostic findings in three consecutive patients with confirmed West Nile virus infection suggest that the virus also attacks the spinal cord in humans.

1 January 2012 in Frontiers in Neurology
Verified
Journal Article
Open access
ALA. Arturo Leis
A. Arturo Leis
DSDobrivoje Stokic
Dobrivoje Stokic
The most common neuromuscular manifestation of West Nile virus (WNV) infection is a poliomyelitis syndrome with asymmetric paralysis variably involving one (monoparesis) to four limbs (quadriparesis), with or without brainstem involvement and respiratory failure. This syndrome of acute flaccid paralysis may occur without overt fever or meningoencephalitis. Although involvement of anterior horn cells in the spinal cord and motor neurons in the brainstem are the major sites of pathology responsible for neuromuscular signs, inflammation also may involve skeletal or cardiac muscle (myositis, myocarditis), motor axons (polyradiculitis), and peripheral nerves [Guillain–Barré syndrome (GBS), brachial plexopathy]. In addition, involvement of spinal sympathetic neurons and ganglia provides an explanation for autonomic instability seen in some patients. Many patients also experience prolonged subjective generalized weakness and disabling fatigue. Despite recent evidence that WNV may persist long-term in the central nervous system or periphery in animals, the evidence in humans is controversial. WNV persistence would be of great concern in immunosuppressed patients or in those with prolonged or recurrent symptoms. Support for the contention that WNV can lead to autoimmune disease arises from reports of patients presenting with various neuromuscular diseases that presumably involve autoimmune mechanisms (GBS, other demyelinating neuropathies, myasthenia gravis, brachial plexopathies, stiff-person syndrome, and delayed or recurrent symptoms). Although there is no specific treatment or vaccine currently approved in humans, and the standard remains supportive care, drugs that can alter the cascade of immunobiochemical events leading to neuronal death may be potentially useful (high-dose corticosteroids, interferon preparations, and intravenous immune globulin containing WNV-specific antibodies). Human experience with these agents seems promising based on anecdotal reports.

1 November 1995 in Electroencephalography and Clinical Neurophysiology/Evoked Potentials Section
Verified
Journal Article
Closed access
ITI.M. Tarkka
I.M. Tarkka
DSDobrivoje Stokic
Dobrivoje Stokic
LBL.F.H. Basile
L.F.H. Basile
APA.C. Papanicolaou
A.C. Papanicolaou